Takeda Pharmaceutical's 6-K filing reports revenues of JPY 1,208 billion for Q1 FY2024, up 14.1% from the same period last year, and a net profit of JPY 95.3 billion, a 6.6% increase. The period ended June 30, 2024, shows growth in Plasma-Derived Therapies, Gastroenterology, Oncology, and Rare Diseases, while Neuroscience faced a sales decline due to generic competition.